Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Durvalumab (Imfinzi) is a PD-L1–blocking antibody that has 3 indications for non–small cell lung cancer (NSCLC). February ...

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

MSFT, AZN, and BLK earn praise in fresh Zacks reports, with AI, pharma pipelines, and AUM growth fueling long-term outlooks.

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to buy a great stock on the cheap. The post At a bargain-basement valuation now, ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key therapeutic advances, standout presentations, emerging trends in oncology treatment, ...

Vickers was right. AstraZeneca, the global pharmaceutical company that generated more than $54 billion in revenue in 2024, is now suing Utah Attorney General Derek Brown and Utah Insurance ...